Wei-peng Hu

Wei-peng Hu


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Frontiers in Neuroscience
Verified
Journal Article
Open access
YXYu Xiong
Yu Xiong
JSJianping Song
Jianping Song
XHXinyue Huang
Xinyue Huang
ZPZhigang Pan
Zhigang Pan
RGRoland Goldbrunner
Roland Goldbrunner
PSPantelis Stavrinou
Pantelis Stavrinou
Ischemic stroke is defined as an infarction in the brain, caused by impaired cerebral blood supply, leading to local brain tissue ischemia, hypoxic necrosis, and corresponding neurological deficits. At present, revascularization strategies in patients with acute ischemic stroke include intravenous thrombolysis and mechanical endovascular treatment. However, due to the short treatment time window (<4.5 h) and method restrictions, clinical research is focused on new methods to treat ischemic stroke. Exosomes are nano-sized biovesicles produced in the endosomal compartment of most eukaryotic cells, containing DNA, complex RNA, and protein (30–150 nm). They are released into surrounding extracellular fluid upon fusion between multivesicular bodies and the plasma membrane. Exosomes have the characteristics of low immunogenicity, good innate stability, high transmission efficiency, and the ability to cross the blood–brain barrier, making them potential therapeutic modalities for the treatment of ischemic stroke. The seed sequence of miRNA secreted by exosomes is base-paired with complementary mRNA to improve the microenvironment of ischemic tissue, thereby regulating downstream signal transduction activities. With exosome research still in the theoretical and experimental stages, this review aims to shed light on the potential of exosomes derived from mesenchymal stem cells in the treatment of ischemic stroke.

7 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QHQiongling Huang
Qiongling Huang
YHYanjun Huang
Yanjun Huang
CCChunhui Chen
Chunhui Chen
YZYizheng Zhang
Yizheng Zhang
JZJiao Zhou
Jiao Zhou
CZChaohui Zheng
Chaohui Zheng
This study aimed to investigate the prognostic impact of lymphovascular and perineural invasions in patients with squamous cell carcinoma of the tongue who received surgery-based treatment at our institution between January 2013 and December 2020. Patients were divided into four groups based on the presence of perineural (P−/P +) and lymphovascular invasions (V−/V +): P–V−, P–V + , P + V−, and P + V + . Log-rank and Cox proportional hazard models were used to evaluate the association between perineural /lymphovascular invasion and overall survival (OS). Altogether, 127 patients were included, and 95 (74.8%), 8 (6.3%), 18 (14.2%), and 6 (4.7%) cases were classified as P–V−, P–V + , P + V−, and P + V + , respectively. Pathologic N stage (pN stage), tumor stage, histological grade, lymphovascular invasion, perineural invasion, and postoperative radiotherapy were significantly associated with OS (p < 0.05). OS was significantly different among the four groups (p < 0.05). Significant between-group differences in OS were detected for node-positive (p < 0.05) and stage III–IV (p < 0.05) cases. OS was the worst in the P + V + group. Lymphovascular and perineural invasions are independent negative prognostic factors for squamous cell carcinoma of the tongue. Patients with lymphovascular and/or perineural invasion may have significantly poorer overall survival than those without neurovascular involvement.

25 April 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XWXiaohua Wang
Xiaohua Wang
XCXinli Chen
Xinli Chen
FWFan Wu
Fan Wu
YLYingchao Liu
Yingchao Liu
YYYushen Yang
Yushen Yang
HHHefan He
Hefan He
Early biomarkers are needed to identify patients at risk of developing postoperative cognitive dysfunction (POCD). Our objective was to determine neuronal injury-related biomarkers with predictive values for this condition. Six biomarkers (S100β, neuron-specific enolase [NSE], amyloid beta [Aβ], tau, neurofilament light chain, and glial fibrillary acidic protein) were evaluated. According to the first postoperative sampling time, observational studies showed that S100β was significantly higher in patients with POCD than in those without POCD (standardized mean difference [SMD]: 6.92, 95% confidence interval [CI]: 4.44−9.41). The randomized controlled trial (RCT) showed that S100β (SMD: 37.31, 95% CI: 30.97−43.64) and NSE (SMD: 3.50, 95% CI: 2.71−4.28) in the POCD group were significantly higher than in the non-POCD group. The pooled data of observational studies by postoperative sampling time showed significantly higher levels of the following biomarkers in the POCD groups than in the control groups: S100β levels at 1 hour (SMD: 1.35, 95% CI: 0.07−2.64), 2 days (SMD: 27.97, 95% CI: 25.01−30.94), and 9 days (SMD: 6.41, 95% CI: 5.64−7.19); NSE levels at 1 hour (SMD: 0.92, 95% CI: 0.25−1.60), 6 hours (SMD: 0.79, 95% CI: 0.12−1.45), and 24 hours (SMD: 0.84, 95% CI: 0.38−1.29); and Aβ levels at 24 hours (SMD: 2.30, 95% CI: 1.54−3.06), 2 days (SMD: 2.30, 95% CI: 1.83−2.78), and 9 days (SMD: 2.76, 95% CI: 2.25−3.26). The pooled data of the RCT showed that the following biomarkers were significantly higher in POCD patients than in non-POCD patients: S100β levels at 2 days (SMD: 37.31, 95% CI: 30.97−43.64) and 9 days (SMD: 126.37, 95% CI: 104.97−147.76) and NSE levels at 2 days (SMD: 3.50, 95% CI: 2.71−4.28) and 9 days (SMD: 8.53, 95% CI: 7.00−10.06). High postoperative levels of S100β, NSE, and Aβ may predict POCD. The relationship between these biomarkers and POCD may be affected by sampling time.

28 June 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
JZJian-Feng Zhou
Jian-Feng Zhou
YXYu Xiong
Yu Xiong
XKXiaodong Kang
Xiaodong Kang
ZPZhigang Pan
Zhigang Pan
QZQiangbin Zhu
Qiangbin Zhu
PSPantelis Stavrinou
Pantelis Stavrinou
Non-traumatic intracerebral hemorrhage is a highly destructive intracranial disease with high mortality and morbidity rates. The main risk factors for cerebral hemorrhage include hypertension, amyloidosis, vasculitis, drug abuse, coagulation dysfunction, and genetic factors. Clinically, surviving patients with intracerebral hemorrhage exhibit different degrees of neurological deficits after discharge. In recent years, with the development of regenerative medicine, an increasing number of researchers have begun to pay attention to stem cell and exosome therapy as a new method for the treatment of intracerebral hemorrhage, owing to their intrinsic potential in neuroprotection and neurorestoration. Many animal studies have shown that stem cells can directly or indirectly participate in the treatment of intracerebral hemorrhage through regeneration, differentiation, or secretion. However, considering the uncertainty of its safety and efficacy, clinical studies are still lacking. This article reviews the treatment of intracerebral hemorrhage using stem cells and exosomes from both preclinical and clinical studies and summarizes the possible mechanisms of stem cell therapy. This review aims to provide a reference for future research and new strategies for clinical treatment.

31 March 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YXYu Xiong
Yu Xiong
XGXiumei Guo
Xiumei Guo
XHXinyue Huang
Xinyue Huang
XKXiaodong Kang
Xiaodong Kang
JZJianfeng Zhou
Jianfeng Zhou
FZFeng Zheng
Feng Zheng
Background: Although some studies have shown that tranexamic acid is beneficial to patients with intracranial haemorrhage, the efficacy and safety of tranexamic acid for intracranial haemorrhage remain controversial. Method: The PubMed, EMBASE, and Cochrane Library databases were systematically searched. The review followed PRISMA guidelines. Data were analyzed using the random-effects model. Results: Twenty-five randomized controlled trials were included. Tranexamic acid significantly inhibited hematoma growth in intracranial hemorrhage (ICH) and traumatic brain injury (TBI) patients. (ICH: mean difference -1.76, 95%CI -2.78 to -0.79, I2 = 0%, P < .001; TBI: MD -4.82, 95%CI -8.06 to -1.58, I2 = 0%, P = .004). For subarachnoid hemorrhage (SAH) patients, it significantly decreased the risk of hydrocephalus (OR 1.23, 95%CI 1.01 to 1.50, I2 = 0%, P = .04) and rebleeding (OR, 0.52, 95%CI 0.35 to 0.79, I2 = 56% P = .002). There was no significance in modified Rankin Scale, Glasgow Outcome Scale 3–5, mortality, deep vein thrombosis, pulmonary embolism, or ischemic stroke/transient ischemic. Conclusion: Tranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.

21 July 2023 in Medicine
Verified
Journal Article
Open access
YLYingchao Mm Liu
Yingchao Mm Liu
XCXinli Mm Chen
Xinli Mm Chen
XWXiaohua Mm Wang
Xiaohua Mm Wang
HZHuohu Zhong
Huohu Zhong
HHHefan He
Hefan He
FZFeng Zheng
Feng Zheng
Background: Postoperative nausea and vomiting (PONV) is one of the common adverse reactions after surgery. Recent randomized controlled trials (RCTs) investigating antiemetic drugs suggest that aprepitant has the strongest antiemetic effect of any single drug. This meta-analysis aimed to explore the efficacy of aprepitant for preventing PONV based on the existing literature. Methods: To identify RCTs investigating the use of aprepitant for PONV prevention, we searched PubMed, Embase, and Cochrane Library databases for articles published prior to March 20, 2022. Seventeen RCTs were identified, with 3299 patients, meeting the inclusion criteria. PONV incidence, complete response, 80 mg aprepitant combined with dexamethasone and ondansetron, vomiting, nausea, and analgesic dose-response were the main outcomes measured. Results: Compared with the control group, PONV incidence was significantly reduced among those receiving aprepitant (odds ratio [OR]: 0.34; 95% confidence interval [CI]: 0.26, 0.44; P < .0001), with a more complete response (OR: 1.35; 95% CI: 1.14, 1.59; P = .0004). Supplementation of 80 mg aprepitant in combination with dexamethasone and ondansetron substantially improved the effects of PONV (OR: 0.36; 95% CI: 0.16, 0.82; P = .01). Further, administration of 80 mg aprepitant was better at preventing vomiting than nausea (OR: 8.6; 95% CI: 3.84, 19. 29; P < .00001). No statistically significant difference between the dose-response of analgesics was identified (mean difference: −1.09; 95% CI: −6.48, 4.30; P = .69). The risk of bias was assessed independently by paired evaluators. Conclusion: Aprepitant effectively reduces the incidence of PONV; however, the effects of postoperative analgesia require further exploration.